ArticlePalliative & supportive care2017
Chimeric antigen receptor T-cell neuropsychiatric toxicity in acute lymphoblastic leukemia.
Article in Palliative & supportive care, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- The Struggle Between Chimeric Antigen Receptor T-Cell Therapy and Neurological Complications in Acute Lymphoblastic Leukemia Treatment.Current issues in molecular biology · 2025Review
- Cell Immunotherapy against Melanoma: Clinical Trials Review.International journal of molecular sciences · 2023Review
- Paraneoplastic Neuropathies: What's New Since the 2004 Recommended Diagnostic Criteria.Frontiers in neurology · 2021Review
- The Influence of Chimeric Antigen Receptor Structural Domains on Clinical Outcomes and Associated Toxicities.Cancers · 2020Article
- Considerations for setting occupational exposure limits for novel pharmaceutical modalities.Regulatory toxicology and pharmacology : RTP · 2020Review
- CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead.Journal of immunology research · 2020Review
- CAR T Cell Therapy for Hematological Malignancies.Current medical science · 2019Review
- Review
- Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2019Review
- Review
- Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy.Biomarker research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Chimeric antigen receptor T cells are used in the treatment of B-cell leukemias. Common chimeric antigen receptor T-cell toxicities can range from mild flu-like symptoms, such as fever and myalgia, to a more striking neuropsychiatric toxicity that can present as discrete neurological symptoms and delirium. We report here two cases of chimeric antigen receptor T-cell neuropsychiatric toxicity, one who presented as a mild delirium and aphasia that resolved without intervention, and one who presented with delirium, seizures, and respiratory insufficiency requiring intensive treatment. The current literature on the treatment and proposed mechanisms of this clinically challenging chimeric antigen receptor T-cell complication is also presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.